Advancements in Biomarker-driven Care for Gynecological Malignancies,
an Industry Supported Symposium
GSK welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to view the Advancements in Biomarker-driven Care for Gynecological Malignancies Industry Supported Symposium Enduring Educational Materials that were presented during the WAGO 2023 Annual Meeting.
GSK is proud to partner with experts in the field to bring you educational resources to support you and your patients.
The target audience for this activity is community and academic gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other providers who treat patients with gynecologic malignancies.
Upon completion of the activities in this series, learners will demonstrate:
- Review up-to-date advances in biomarker-driven management of patients with ovarian or endometrial cancer and implications for outcomes.
- Discuss how currently actionable biomarkers impact treatment selection for these diseases.
- Consider the future evolution in biomarkers and management of patients with gynecological malignancies.
- Debra Richardson, MD, University of Oklahoma Health Sciences Center
Presentation MaterialsAdvancements in Biomarker-driven Care for Gynecological Malignancies, an Industry Supported Symposium at the WAGO 2023 Annual Meeting
Presented on Thursday, June 154, 2023 | 12:20 pm – 1:50 pm PST
Enduring Educational Materials will be available on demand for six months following the live presentation.